L-Carnitine Injection: What It Is, Where to Get It Prescribed, and What It Costs

L-carnitine is not a peptide. It is a small quaternary ammonium compound — 3-hydroxy-4-N-trimethylaminobutyrate — that the liver and kidneys synthesise from the amino acids lysine and methionine. Its job is narrow and well characterised: it carries long-chain fatty acids across the inner mitochondrial membrane so they can be oxidised for energy. Without carnitine, long-chain fats cannot reach the part of the cell that oxidises them.

The body keeps a pool of it, and the large majority sits in skeletal and cardiac muscle, the tissues that rely most on fat as fuel. A 2004 review in the Annals of the New York Academy of Sciences describes how the pool is maintained: dietary absorption, a modest rate of synthesis, and very efficient renal reabsorption — 90 to 99 percent of what is filtered is taken back at normal concentrations.

Carnitine exists as two mirror-image forms. Only the L form is biologically active, and pharmaceutical carnitine is always the L form, which is why the approved drug is named levocarnitine. Dietary carnitine comes mostly from red meat and, to a lesser extent, dairy; the body makes the rest. People absorb 54 to 87 percent of what is in food, while large oral supplement doses are absorbed at only 14 to 18 percent, because active transport saturates and the remainder is degraded by gut bacteria.

It is not a stimulant, not a hormone and not a thermogenic. It is not a fat-loss drug in the sense that a GLP-1 medication is: it does not suppress appetite, and its presence does not make the body oxidise more fat than the demand for energy calls for. It is a cofactor in a pathway, and the pathway still has to be driven by activity.

The core mechanism is textbook biochemistry. A long-chain fatty acid is attached to carnitine by the enzyme CPT1 on the outer mitochondrial membrane, carried through the inner membrane by a dedicated transporter, and released by CPT2 inside for beta-oxidation. This is the rate-limiting step in long-chain fat oxidation, and it is why genuine carnitine deficiency produces muscle weakness and, in severe cases, cardiomyopathy: fat cannot be used, so the body runs on glucose alone.

A second role was described by the Nottingham group in a 2007 review in the Journal of Physiology. During hard exercise the pyruvate dehydrogenase complex produces acetyl-CoA faster than mitochondria can use it. Free carnitine soaks up the excess as acetyl-carnitine, keeping the enzyme running and limiting lactate accumulation. Free carnitine in muscle therefore drops during intense exercise, and the hypothesis is that raising muscle carnitine content gives more buffering capacity.

The same group tested this in people. A 2011 paper in the Journal of Physiology gave fourteen healthy men either 2 g of L-carnitine tartrate with 80 g of carbohydrate, or carbohydrate alone, twice a day for 24 weeks, with muscle biopsies. Muscle total carnitine rose 21 percent in the carnitine group and did not change in controls; at low intensity the carnitine group used 55 percent less muscle glycogen, at high intensity muscle lactate was 44 percent lower, and work output in a 30-minute performance trial rose 11 percent from baseline. Two details are essential. The carbohydrate was there to raise insulin, which is what drives carnitine into muscle; without it, oral carnitine does not change muscle content. And it took 24 weeks. Muscle carnitine loading is slow.

A 2018 review in Nutrients, supported by a carnitine manufacturer, summarises smaller human trials describing lower markers of muscle damage and free-radical formation after exercise, and less reported soreness, in supplemented volunteers. The proposed mechanism is improved endothelial function and oxygen delivery to working muscle. The review also notes studies in older adults reporting reduced fatigue.

This is the only indication where the evidence is definitive, and it is the one the approved drug exists for: inborn errors of metabolism that cause secondary carnitine deficiency, and end-stage renal disease where dialysis strips carnitine from the blood. That is replacement of something measurably missing, a different proposition from supplementing someone whose levels are normal.

There is a lot of human data here, and it should be described exactly. A 2016 meta-analysis in Obesity Reviews pooled nine randomised controlled trials (911 participants) and reported that people receiving carnitine lost on average 1.33 kg more than controls, with the effect shrinking the longer a trial ran. A 2020 update in Pharmacological Research pooled 43 trials and reported differences of 1.13 kg in body weight and 1.16 kg in fat mass, with no significant difference in body-fat percentage or waist circumference, and with the effect confined to overweight and obese participants in trials that added lifestyle change. A separate 2020 meta-analysis of 37 trials in Clinical Nutrition ESPEN reported 1.21 kg in body weight, found that only that result held when restricted to high-quality trials, and placed the maximum oral dose-response at 2,000 mg per day.

Three things follow. The effect is reproducible across dozens of trials. It is modest — around a kilogram over a study period, alongside diet and exercise. And every one of those trials used oral carnitine, so the numbers describe a different product and route than the one on this page.

The 2011 biopsy study above is the clearest performance result, and it required six months of oral loading with carbohydrate. The recovery literature summarised in Nutrients in 2018 consists of smaller trials with biochemical endpoints — creatine kinase, oxidative-stress markers, soreness ratings — rather than return-to-training times.

A 2007 randomised controlled trial in the American Journal of Clinical Nutrition gave 2 g of oral L-carnitine daily for six months to centenarians and reported reduced physical and mental fatigue scores versus placebo — a specific population, but a properly controlled trial. In dialysis patients, the CHIEF trials in the American Journal of Kidney Diseases in 2001 gave intravenous L-carnitine after each session for 24 weeks; the primary endpoint of peak oxygen uptake was not met, and patient-rated fatigue improved on the secondary analysis.

Randomised controlled trials of L-carnitine in humans exist in large numbers, and three meta-analyses of them have been published. That puts it in a different evidence tier from most peptides on this site. The trials are almost entirely oral, mostly 1 to 3 g per day for 8 to 24 weeks; the intravenous trials are in dialysis patients. There are no randomised trials of low-dose intramuscular L-carnitine in healthy adults, which is the format on this page, so what the injectable version does in that population is extrapolated rather than measured.

• It does not establish that injecting carnitine produces the changes the oral trials describe. That trial has not been run.
• It does not establish an effect in people whose carnitine status is already normal.
• It does not establish a meaningful change in body-fat percentage or waist circumference — two of the three meta-analyses looked and did not find one.
• It does not establish a performance benefit without prolonged loading with carbohydrate.
• It does not establish efficacy for weight, exercise or fatigue as an approved indication. The approved product is approved for carnitine deficiency and nothing else.

An intramuscular injection puts carnitine into circulation quickly, and plasma levels fall back within a day or two because renal reabsorption saturates and the excess is cleared. Most people notice nothing in the first week beyond the injection itself. Some describe feeling slightly more energetic on injection days; some notice a faint body odour, a known and dose-related effect of carnitine metabolism.

If muscle carnitine content is going to change, the human biopsy work says it changes slowly and in the presence of insulin. A four-week vial is therefore the start of a course rather than the whole of it, and what prescribers describe in this window is subjective — training tolerance, recovery between sessions — rather than measurable.

The oral trials that produced measurable results ran 8 to 24 weeks. Prescribers generally describe carnitine as a background intervention over months, reviewed at refill against whether the person is doing the work it is meant to support.

There is no withdrawal and no rebound. Circulating carnitine returns to the body's own set point within days, because synthesis and renal reabsorption were never switched off. Whether anything persists depends on whether training or body composition changed during the course.

The directions are written in millilitres and in insulin-syringe units because that is what you can read off the barrel. 0.50 mL is 50 units on a U-100 syringe. There is no calculation to do; the number is printed on your medication, and your physician sets it.

Intramuscular means into the muscle, not the fat layer under the skin. The usual sites are the deltoid, the upper outer thigh, or the upper outer quadrant of the buttock, rotated between doses. An intramuscular injection uses a longer needle than a subcutaneous one, and the pharmacy supplies the right one.

Once daily on weekdays gives 20 doses per vial and about four weeks of coverage. Two days off is a practical schedule rather than a pharmacological one; carnitine clears quickly and there is no accumulation to manage. One vial per fill, always — refills run on a 28-day cycle.

Refrigerated, and it ships that way in insulated packaging with ice packs. Beyond-use dating runs from first puncture and is on the label. Do not freeze it.

Lipo-B is B12 with the methionine–inositol–choline lipotropic trio, and Lipo-Mino-Mix-C is the extended multi-ingredient version. Both are described around liver fat handling and B-vitamin status rather than the mitochondrial fatty-acid shuttle. L-carnitine is a single active with a single well-characterised job and a much deeper trial base. Whether one, the other or both is appropriate is the physician's decision.

NAD+ is a coenzyme in the electron-transport and sirtuin pathways, so both sit in the "cellular energy" conversation. They act at different points: carnitine gets fat into the mitochondrion, NAD+ is consumed in oxidising it. NAD+ has a smaller human trial base. There is no head-to-head trial.

The oral supplement is what nearly all the trial evidence used, at 1 to 3 g a day. The trade-off is absorption — roughly 14 to 18 percent of a large oral dose — and, for muscle loading, months of carbohydrate alongside. The injection delivers the full dose with physician oversight. Neither route has been shown superior for the off-label uses people actually ask about.

L-carnitine is supplied as a vial and syringe only; there is no pepti Pen cartridge for it.